Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
EMT-6 murine mammary tumors were made resistant to cis-diamminedichloroplatinum (II) (CDDP), carboplatin, cyclophosphamide (CTX), or thiotepa in vivo by treatment of tumor-bearing animals with the drug during a 6-month period. In spite of high levels of in vivo resistance, no significant resistance was observed when the cells from these tumors were exposed to the drugs in vitro. The pharmacokinetics of CDDP and CTX were altered in animals bearing the respective resistant tumors. The resistance of all tumor lines except for the EMT-6/thiotepa decreased during 3 to 6 months in vivo passage in the absence of drugs. These results indicate that very high levels of resistance to anticancer drugs can develop through mechanisms that are expressed only in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vivo studies have demonstrated that tumors exposed to repeated alkylating agent treatment in murine models developed significant resistance, which was not observed when the same cells were cultured in vitro, underscoring the essential role of stromal interactions in modulating therapeutic response [146].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [146]
Citations
Cites
Ellman, G. L. (1959) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(59)90090-6 · Cited by 26,311
Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent
Sedlak, J., & Lindsay, R. H. (1968) · Analytical Biochemistry · doi:10.1016/0003-2697(68)90092-4 · Cited by 8,077
Teicher, B. A., Lazo, J. S., & Sartorelli, A. C. (1981) · PubMed · Cited by 555
Self-citationThe genetic origin of drug resistance in neoplasms: implications for systemic therapy.
Goldie, J. H., & Coldman, A. J. (1984) · PubMed · Cited by 511
A fluorometric assay for glutathione
Cohn, V. H., & Lyle, J. (1966) · Analytical Biochemistry · doi:10.1016/0003-2697(66)90286-7 · Cited by 441
(1972) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/49.3.735 · Cited by 397
Presence of a growth-stimulating factor in serum following primary tumor removal in mice.
Fisher, B., Gündüz, N., Coyle, J., Rudock, C., & Saffer, E. (1989) · PubMed · Cited by 361
Teicher, B. A., Holden, S. A., Kelley, M. J., Shea, T. C., Cucchi, C. A., Rosowsky, A., Henner, W. D., & Frei, E. (1987) · PubMed · Cited by 312
Self-citationTherapeutic attack of hypoxic cells of solid tumors: presidential address.
Sartorelli, A. C. (1988) · PubMed · Cited by 278
Chapter 15 Serial Cultivation of Normal Human Epidermal Keratinocytes
Rheinwald, J. G. (1980) · Methods in Cell Biology · doi:10.1016/s0091-679x(08)60769-4 · Cited by 264
Quantitative model for multiple levels of drug resistance in clinical tumors.
Goldie, J. H., & Coldman, A. J. (1983) · PubMed · Cited by 191
Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei, E., Teicher, B. A., Holden, S. A., Cathcart, K. N. S., & Wang, Y. (1988) · PubMed · Cited by 188
Self-citationAlkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Teicher, B. A., Cucchi, C. A., Lee, J. B., Flatow, J., Rosowsky, A., & Frei, E. (1986) · PubMed · Cited by 160
Self-citationCellular Radiosensitivity and Tumor Radiation Response in the EMT6 Tumor Cell System
Rockwell, S., & Kallman, R. F. (1973) · Radiation Research · doi:10.2307/3573534 · Cited by 151
In vivo-in vitro tumor systems: new models for studing the response of tumours to therapy.
Rockwell, S. (1977) · PubMed · Cited by 145
Establishment of cross-resistance profiles for new agents.
Fm, S., He, S., Trader, M. W., Laster, W. R., Griswold, D. P., & Th, C. (1983) · PubMed · Cited by 142
Use of serum tumor markers in cancer diagnosis and management.
Bates, S. E., & Longo, D. L. (1987) · PubMed · Cited by 133
Patterns of Resistance and Therapeutic Synergism among Alkylating Agents1
Schabel, F. M., Trader, M. W., Laster, W. R., Wheeler, G. P., & Witt, M. H. (2015) · Antibiotics and chemotherapy/Antibiotica et chemotherapia · doi:10.1159/000401484 · Cited by 130
Mechanisms of Drug Resistance in Neoplastic Cells
(1988) · Elsevier eBooks · doi:10.1016/c2013-0-07655-4 · Cited by 118
In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).
Seeber, S., Osieka, R., Schmidt, C. G., Achterrath, W., & Crooke, S. T. (1982) · PubMed · Cited by 116
Teicher, B. A., Holden, S. A., & Jacobs, J. L. (1987) · PubMed · Cited by 75
Self-citationHerman, T. S., Teicher, B. A., Chan, V., Collins, L. S., Kaufmann, M. E., & Loh, C. (1988) · PubMed · Cited by 70
Self-citationHerman, T. S., Teicher, B. A., Cathcart, K. N. S., Kaufmann, M. E., Lee, J. B., & Lee, M.-H. (1988) · PubMed · Cited by 64
Self-citationDrummer, O. H., Proudfoot, A. D., Howes, L. G., & Louis, W. J. (1984) · Clinica Chimica Acta · doi:10.1016/0009-8981(84)90248-1 · Cited by 60
Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C
Keyes, S. R., Heimbrook, D. C., Fracasso, P. M., Rockwell, S., Sligar, S. G., & Sartorelli, A. C. (1985) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(85)90053-6 · Cited by 56
"Role of mathematical modeling in protocol formulation in cancer chemotherapy".
Coldman, A. J., & Goldie, J. H. (1985) · PubMed · Cited by 54
Varnes, M. E., & Biaglow, J. E. (1979) · PubMed · Cited by 52
Development of drug resistance in a murine mammary tumour
McMillan, T. J., Stephens, T. C., & Steel, G. G. (1985) · British Journal of Cancer · doi:10.1038/bjc.1985.265 · Cited by 30
Development of fluorescence between o-phthaldialdehyde and thiols
Jocelyn, P. C., & Kamminga, A. H. (1970) · Analytical Biochemistry · doi:10.1016/0003-2697(70)90067-9 · Cited by 29
Pharmacokinetics of the absorption, distribution, and elimination of melphalan in the dog.
Furner, R. L., Brown, R. K., & Duncan, G. F. (1977) · PubMed · Cited by 25
A Dose-Response Study of Resistance of Leukemia L1210 to Cyclophosphamide2
DeWys, W. D. (1973) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/50.3.783 · Cited by 23
Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
D’Incalci, M., Torti, L., Damia, G. L. M., Erba, E., Morasca, L., & Garattini, S. K. (1983) · PubMed · Cited by 21
Paraendocrine syndromes of cancer.
Wd, O. (1989) · PubMed · Cited by 19
Nitrosourea-misonidazole combination chemotherapy: Effect on KHT sarcomas, marrow stem cells and gut
Mulcahy, R. T., Siemann, D. W., & Sutherland, R. M. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.135 · Cited by 18
Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line.
Frondoza, C. G., Trivedi, S. M., & Rl, H. (1982) · PubMed · Cited by 16
Stephens, T. C., Adams, K., & Peacock, J. H. (1984) · British Journal of Cancer · doi:10.1038/bjc.1984.141 · Cited by 14
A Comparison of Radiation-Sensitizing Ability and Cell Uptake for NDPP and Ro-07-0582
Wong, T. W., & Whitmore, G. F. (1977) · Radiation Research · doi:10.2307/3574718 · Cited by 12
Experimental basis and clinical experience with non-cross-resistant combinations in solid tumours
Seeber, S., Dimitriadis, K., ̈tte, J. S., & Schmidt, C. G. (1984) · Cancer Treatment Reviews · doi:10.1016/0305-7372(84)90043-4 · Cited by 10
Brown, R. K., Duncan, G., & Hill, D. L. (1980) · PubMed · Cited by 10
Research works printed but not linked: 9
- COHEN, V.H., ANAL BIOCHEM 14: 434 (1986).
- FREI, E, MECHANISMS DRUG RESI 69 (1988).
- HERMAN, T.S., EFFECT OF HYPERTHERMIA ON THE ACTION OF CIS-DIAMMINEDICHLOROPLATINUM(II), RHODAMINE 1232 [TETRACHLOROPLATINUM(II)], RHODAMINE 123, AND POTASSIUM TETRACHLOROPLATINATE INVITRO AND INVIVO, CANCER RESEARCH 48: 2335 (1988).
- ODELL, W.D., ADV INTERNAL MED 34: 325 (1989).
- ROCKWELL, S, CYTOTOXIC AND RADIOSENSITIZING EFFECTS OF HYPOXIC CELL SENSITIZERS ON EMT6 MOUSE MAMMARY-TUMOR CELLS INVIVO AND INVITRO, BRITISH JOURNAL OF CANCER 37: 212 (1978).
- ROCKWELL, S, INVIVO-INVITRO TUMOR SYSTEMS - NEW MODELS FOR STUDYING RESPONSE OF TUMORS TO THERAPY, LABORATORY ANIMAL SCIENCE 27: 831 (1977).
- SARTORELLI, A.C., CANCER RES 48: 775 (1988).
- SCHABEL, F.M., PHARMACOL THERAPEUT 20: 282 (1983).
- TEICHER, B.A., DRUG RESISTANCE MAMM 2: 1 (1988).
Cited by
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154
Metadata
- Authors
- Teicher, B., Herman, T., Holden, S., Wang, Y., Pfeffer, M., Crawford, J., & Frei, E.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Venue
- Science
- Published
- 1990-03-23
- Volume
- 247
- Issue
- 4949
- Pages
- 1457-1461
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1983075270
- Cited by
- 327
- References
- 39
- Citations by year
- 2026: 2 · 2025: 5 · 2023: 5 · 2022: 5 · 2021: 2 · 2020: 6 · 2019: 7 · 2018: 9 · 2017: 14 · 2016: 11 · 2015: 10 · 2014: 13 · 2013: 8 · 2012: 10
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1p01ca038497-01)
- National Cancer Institute (P01-CA 38497)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- alkylating agent resistance, cisplatin resistance, carboplatin, cyclophosphamide, thiotepa, pharmacokinetics, tumor-bearing animals, drug resistance reversal
- MeSH terms
- Alkylating Agents, Animals, Antineoplastic Agents, Cisplatin, Cyclophosphamide, Drug Resistance, Kidney, Liver, Mammary Neoplasms, Experimental, Mice, Inbred BALB C, Organoplatinum Compounds, Sulfhydryl Compounds, Thiotepa, Tissue Distribution, Tumor Cells, Cultured, Carboplatin, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.